RESUMEN
INTRODUCTION: Intraosseous (IO) needle insertion is a key adjunctive procedure in the care of critically ill and injured patients in a variety of settings, including the battlefield. The NIO is a new, fully disposable, single-piece, IO device with potential practical advantages under austere conditions. We sought to compare the efficacy and safety of the NIO to an established, well-studied device, the EZIO, when used for resuscitative vascular access in the emergency department (ED). METHODS: Retrospective, single-center, quasi-experimental, before-and-after, observational cohort study performed at an urban, tertiary-care hospital ED among adult patients receiving IO access during resuscitation. The before/NIO period lasted from July 1, 2019, to May 31, 2020, and the EZIO/after period from June 1, 2020, to April 30, 2021. Patient demographics, prehospital treatment, ED presentation, characteristics and results of IO insertion(s), potential procedure-associated adverse events, and ED and hospital outcomes were abstracted from the medical record. The primary outcome, rate of first-pass success (FPS), was compared between the NIO and EZIO periods using multivariable regression after adjustment for potential confounding factors. RESULTS: We enrolled 63 total patients/66 limbs (mean age 61 ± 18, 51% female), 34 patients/35 limbs during the NIO period and 29 patients/31 limbs during the EZIO period. The most common reason for IO insertion was cardiac arrest (40/63, 63%), followed by respiratory failure, trauma, and sepsis. The majority of IO insertions were performed at the proximal tibia (58/66, 88%) by senior emergency medicine residents or faculty. The overall rate of FPS was 53/66 (80%), 24/35 (69%) with the NIO compared to 29/31 (94%) with the EZIO. After multivariable modeling, the odds of FPS with the NIO vs. the EZIO was 0.19 (95% CI, 0.01-1.5, P = .16). Procedure-related adverse events were infrequent in both groups. In-hospital mortality was 45/63 (71%). CONCLUSIONS: We found that the NIO device was associated with a lower-than-expected rate of FPS compared to the EZIO device, although not significantly different after adjusting for between-group imbalances and considering limitations in the study design. Further, prospective research into the efficacy and safety of the NIO is needed before clinical use can be encouraged.
Asunto(s)
Servicios Médicos de Urgencia , Adulto , Humanos , Femenino , Persona de Mediana Edad , Anciano , Masculino , Servicios Médicos de Urgencia/métodos , Estudios Retrospectivos , Estudios Prospectivos , Servicio de Urgencia en Hospital , Resucitación/métodos , Infusiones IntraóseasRESUMEN
BACKGROUND: Isolated complaint of dysuria in an adolescent is a rare presentation for acute perforated appendicitis. Acute appendicitis typically involves vague periumbical pain that migrates to the right lower quadrant, associated with pain, nausea, and loss of appetite. There have been case reports of associated pyuria and dysuria in addition to classical symptoms, but to our knowledge, this is the first case with isolated dysuria presenting to an emergency department (ED). CASE REPORT: A 14-year-old boy presented to the ED with 3 days of dysuria and subsequent sensation of urinary retention. Urine dip showed occult blood without white cells or nitrites. A bedside renal/bladder point-of-care ultrasound (POCUS) did not show evidence of obstruction. However, it did reveal a retrovesicular fluid collection with an echogenic foci inside suspicious for abscess, likely secondary to ruptured appendicitis. This diagnosis was confirmed with a dedicated right lower quadrant ultrasound, with resultant treatment with i.v. antibiotics and eventual surgical resection of the appendix. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: Pediatric and adolescent patients may present with extremely atypical symptoms of a common disease process. In this case, early use of POCUS in the ED helped to quickly identify an acute surgical process and focus diagnostic and therapeutic interventions.
Asunto(s)
Apendicitis , Adolescente , Apendicitis/diagnóstico , Apendicitis/diagnóstico por imagen , Niño , Disuria/etiología , Servicio de Urgencia en Hospital , Humanos , Masculino , Sistemas de Atención de Punto , UltrasonografíaRESUMEN
STUDY OBJECTIVE: Acute urticaria is a frequent presentation in emergency departments (EDs), urgent care centers, and other clinical arenas. Treatment options are limited if diphenhydramine is the only intravenous antihistamine offered because of its short duration of action and well-known adverse effects. We evaluate cetirizine injection, the first second-generation injectable antihistamine, for acute urticaria in this multicenter, randomized, noninferiority, phase 3 clinical trial. METHODS: Adult patients presenting to EDs and urgent care centers with acute urticaria requiring an intravenous antihistamine were randomized to either intravenous cetirizine 10 mg or intravenous diphenhydramine 50 mg. The primary endpoint was the 2-hour pruritus score change from baseline, with time spent in treatment center and rate of return to treatment centers as key secondary endpoints. Frequency of sedation and anticholinergic adverse effects were also recorded. RESULTS: Among 262 enrolled patients, the 2-hour pruritus score change from baseline for intravenous cetirizine was statistically noninferior to that for intravenous diphenhydramine (-1.6 versus -1.5; 95% confidence interval -0.1 to 0.3), and in favor of cetirizine. Treatment differences also favored cetirizine for mean time spent in treatment center (1.7 versus 2.1 hours; P=.005), return to treatment center (5.5% versus 14.1%; P=.02), lower change from baseline sedation score at 2 hours (0.1 versus 0.5; P=.03), and adverse event rate (3.9% versus 13.3%). CONCLUSION: Intravenous cetirizine is an effective alternative to intravenous diphenhydramine for treating acute urticaria, with benefits of less sedation, fewer adverse events, shorter time spent in treatment center, and lower rates of revisit to treatment center.
Asunto(s)
Cetirizina/normas , Difenhidramina/normas , Urticaria/tratamiento farmacológico , Administración Intravenosa/métodos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Canadá , Cetirizina/administración & dosificación , Cetirizina/uso terapéutico , Difenhidramina/administración & dosificación , Difenhidramina/uso terapéutico , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Resultado del Tratamiento , Estados UnidosRESUMEN
The diiodobinorsnoutane, bi(5-iodopentacyclo[4.3.0.0(2,4).0(3,8).0(5,7)]non-4-yl) (5), exists in a sterically hindered gauche conformation rather than an anti or an averaged (freely rotating) C2v structure. Density functional theory (DFT) predictions place the gauche conformation 11 kcal/mol more stable than the anti conformation with a barrier of 17 kcal/mol connecting the minima. These are consistent with variable-temperature NMR (17.1 ± 0.8 kcal/mol) estimates and X-ray analysis. Predictions of the torsional profiles of the yet-unsynthesized bromo-, chloro-, and fluoro- analogues show a progressive lowering of the barriers.
RESUMEN
The highly pyramidalized alkene, pentacyclo[4.3.0.0(2,4).0(3,8).0(5,7)]non-4-ene (9), has been generated via treatment of 4,5-diiodopentacyclo[4.3.0.0(2,4).0(3,8).0(5,7)]nonane (12) with n-butyllithium and tert-butyllithium. The title alkene has also been trapped as its Diels-Alder adduct with 1,3-diphenylisobenzofuran, 2,5-dimethylfuran, and spiro[2.4]hepta-4,6-diene. Products resulting from alkyllithium addition to the pyramidalized double bond of 9 have been isolated and fully characterized spectroscopically. The geometry, olefin strain energy, heat of hydrogenation, and relative HOMO/LUMO energies of 9 have been obtained by ab initio calculations at the MP2 and B3LYP levels using the 6-31G* basis set.